PSYCHIATRY RESEARCH is a leading journal published by Elsevier Ireland Ltd, dedicated to advancing the field of psychiatry and mental health through the dissemination of rigorous research. With an impressive impact factor and categorized in the top quartile (Q1) of both Biological Psychiatry and Psychiatry and Mental Health in 2023, this journal ranks 14th in the field of Medicine _ Psychiatry and Mental Health out of 567 journals, and 4th in Neuroscience _ Biological Psychiatry out of 51, showcasing its influence and quality. Since its inception in 1979, PSYCHIATRY RESEARCH has provided a platform for innovative studies, clinical trials, and comprehensive reviews aimed at understanding the complexities of mental health disorders. Although it operates under a traditional access model, the journal remains committed to making vital research available to the academic community, ensuring that both seasoned professionals and budding researchers have access to groundbreaking findings. Positioned as a hub for psychiatric research, it caters to a diverse audience including clinicians, psychologists, and students, empowering them to contribute to the evolving landscape of mental health care.

PSYCHIATRIC QUARTERLY, published by Springer, stands as a pivotal resource in the field of psychiatry and mental health since its inception in 1927. With a reputable Q2 categorization in Psychiatry and Mental Health for 2023, this journal ranks impressively at #77 out of 567 in Scopus, placing it in the top 86th percentile of its category. Covering a diverse range of topics related to mental health, PSYCHIATRIC QUARTERLY aims to disseminate rigorous research findings, theoretical advancements, and clinical insights that contribute to improved mental health practices and policies. Although it does not offer open access, it provides substantial value to researchers, professionals, and students through its comprehensive analyses and scholarly articles. Located in New York, United States, the journal serves as an essential platform for advancing the understanding and treatment of psychiatric disorders, making it an invaluable addition to any academic library or research portfolio.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, published by Lippincott Williams & Wilkins, stands as a pivotal peer-reviewed journal in the fields of pharmacology and psychiatry. Established in 1986, it has garnered a prominent reputation with a 2023 impact factor placing it in the Q2 category for both Pharmacology and Psychiatry and Mental Health. With an impressive Scopus ranking of #227 in the Psychiatry and Mental Health category and #114 in Pharmacology, it serves as an essential platform for researchers seeking to disseminate critical findings on psychopharmacological interventions and their clinical efficacy. The journal’s rigorous peer-review process ensures that only high-quality research is published, making it a trusted resource for professionals and students alike. By focusing on the latest advancements and evidence-based practices, the INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY contributes significantly to the understanding of mental health treatments, fostering ongoing dialogue and innovation in the discipline.

BJPsych Open, published by Cambridge University Press, is a leading open access journal dedicated to the field of psychiatry and mental health. Since its inception in 2015, the journal has provided a platform for disseminating cutting-edge research and evidence-based practices, making significant contributions to the academic community. With an impressive impact factor and currently ranking in the top Q1 quartile of its field, BJPsych Open is recognized for its rigor and relevance, ranking 138 out of 567 journals in psychiatry and mental health according to Scopus, placing it in the 75th percentile. The journal's commitment to open access enhances visibility and accessibility, ensuring that vital research is available to a global audience. Researchers, professionals, and students alike will find valuable insights into contemporary mental health challenges and innovative treatment approaches, making BJPsych Open an essential resource for advancing mental health scholarship.

Australasian Psychiatry is a distinguished peer-reviewed journal published by SAGE Publications Ltd, focusing on the dynamic fields of Psychiatry and Mental Health. With a commendable Q3 ranking in the 2023 category quartiles, it serves as a vital resource for researchers, clinicians, and students alike, contributing to the understanding of mental health issues and advancements in psychiatric practice. Established in 1967, the journal has consistently disseminated original research, clinical reviews, and evidence-based practices, fostering a platform for discussing the contemporary challenges faced by mental health professionals. While operating from the heart of the United Kingdom, it aims to bridge regional insights with global trends, celebrating the diversity of thought in psychiatric discourse. Access to its rich content is through institutional subscriptions, ensuring that valuable research is within reach of dedicated scholars and mental health advocates. As the field evolves, Australasian Psychiatry remains committed to advancing knowledge and practice in mental health, positioning itself as an indispensable part of the academic landscape.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE is a distinguished publication dedicated to advancing the understanding of psychiatric practice and mental health issues within a medical framework. Published by SAGE PUBLICATIONS INC, this journal has been a trusted source in the field since its inception, with its archives dating back to 1973. It offers a comprehensive exploration of psychiatric research, clinical studies, and theoretical advancements that seek to bridge the gap between psychiatry and general medicine. With an impact factor reflective of its quality and relevance, categorized in the Q3 quartile in Psychiatry and Mental Health, this journal stands as a vital resource for researchers, clinicians, and students alike. Although operating on a traditional subscription model, the extensive knowledge shared within its pages contributes significantly to ongoing discussions in psychiatric and mental health education and practice. As the field continually evolves, the INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE remains committed to fostering innovative and impactful scholarship that resonates with professionals navigating the complexities of mental health in clinical contexts.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, a premier academic journal published by TAYLOR & FRANCIS LTD, stands at the forefront of interdisciplinary research in the fields of Biological Psychiatry, Psychiatry, and Mental Health. Based in the United Kingdom, this esteemed journal (ISSN: 1562-2975; E-ISSN: 1814-1412) has become increasingly influential since its inception in 2000, with a remarkable impact factor that reflects its high-quality research contributions. The journal is consistently ranked in the Q1 and Q2 categories across various relevant indices, demonstrating its reputation for excellence within the academic community. With Scopus rankings placing it in the top 20th percentile for Psychiatry and Mental Health, the WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY serves as a vital resource for researchers, professionals, and students seeking to further their understanding of the intricate relationship between biological processes and psychiatric phenomena. Despite being a traditional access journal, it possesses a robust scope that encompasses groundbreaking studies, reviews, and advancements in the understanding of mental health disorders, underlining its importance as a key reference in the advancement of psychiatric science and therapeutic practices.

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, published by MARY ANN LIEBERT, INC, stands as a premier academic journal dedicated to advancing the field of pediatric psychopharmacology. With a rich history of publication spanning from 1990 to 2024, this journal presents cutting-edge research that informs clinical practices and policy decisions impacting the mental health of children and adolescents. Ranked in the Q2 category for both Pediatrics, Perinatology and Child Health and Pharmacology (medical) as of 2023, it reflects its critical contribution to these fields, along with a respectable Q3 status in Psychiatry and Mental Health. Researchers and practitioners benefit from the journal's rigorous peer-reviewed articles, which delve into the efficacy, safety, and ethical implications of pharmacological treatments tailored for young populations. Although the journal does not currently offer Open Access, it remains a vital resource for anyone engaged in child and adolescent health research and treatment strategies. Its commitment to fostering dialogue and innovation in psychopharmacology ensures its pivotal role in shaping future standards and practices in this essential area of medical science.

The American Journal of Psychiatry, published by the renowned American Psychiatric Publishing, Inc., stands as a premier platform in the field of Psychiatry and Mental Health. With its inaugural edition released in 1945, this esteemed journal has consistently provided a wealth of knowledge, shaping the landscape of psychiatric research and practice globally. Notably, in the latest 2023 Scopus rankings, it achieved an impressive rank of #7 out of 567 journals in its category, placing it in the top 2% percentile, indicative of its substantial impact within the field. The journal is committed to publishing high-quality, peer-reviewed original research, clinical studies, and reviews that advance psychiatric knowledge and treatment options. Although it does not currently offer open access, its contributions are vital for researchers, clinicians, and students dedicated to improving mental health care and understanding complex mental health disorders. As an essential resource, it continues to foster scholarly communication among professionals who are at the forefront of psychiatric science.

Therapeutic Advances in Psychopharmacology is a leading open-access journal published by SAGE Publications Ltd, focusing on the dynamic integration of pharmacological therapies and psychological health. Since its inception in 2011, this journal has made a significant impact on the fields of pharmacology and psychiatry, consistently earning a Q1 ranking in both categories as of 2023, reflecting its esteemed position within the scientific community. With an impressive Scopus rank placing it in the top 15% across relevant disciplines, the journal serves as a vital platform for researchers, professionals, and students eager to explore cutting-edge advancements in psychopharmacology. The open-access model, established in 2019, ensures that groundbreaking research is accessible to a wide audience, fostering collaboration and innovation in therapeutic strategies for mental health disorders. Through the dissemination of high-quality research and reviews, Therapeutic Advances in Psychopharmacology is committed to advancing understanding and practice within this critical field.